Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3.
David Neal FranzJohn A LawsonZuhal YapiciHiroko IkedaTilman PolsterRima NabboutPaolo CuratoloPetrus J de VriesDennis J DlugosFabian HerbstSeverine PeyrardDiana PelovJacqueline A FrenchPublished in: Epilepsia (2021)
The final analysis of EXIST-3 demonstrated the sustained efficacy of everolimus as adjunctive therapy in patients with TSC-associated treatment-refractory seizures, with a tolerable safety profile.